Early Warning System

IFC-39029

Carnelian

Early Warning System

Carnelian

IFC-39029

Quick Facts

Countries	Colombia
Financial Institutions	International Finance Corporation (IFC)
Status	Approved
Bank Risk Rating	B
Voting Date	2017-07-26
Borrower	UNIMED PHARMACEUTICALS LIMITED
Investment Type(s)	Equity
Investment Amount (USD)	$ 90.00 million
Project Cost (USD)	$ 90.00 million

Project Description

The proposed project includes an IFC equity investment of US$ 90million to support the Procaps capex program. The capex includes building and operation of new greenfield manufacturing plants, expansion of existing production plans, investments in new technologies, and brand acquisition activities. Procaps develops, produces and markets packaged pharmaceutical drugs and advanced drug delivery technologies (i.e., softgel capsules).

Investment Description

- International Finance Corporation (IFC)

Contact Information

ACCOUNTABILITY MECHANISM OF IFC

The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org. You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org/